Literature DB >> 26454646

Genetic Counselors' Experiences Regarding Communication of Reproductive Risks with Autosomal Recessive Conditions found on Cancer Panels.

Sarah Mets1, Rebecca Tryon2, Patricia McCarthy Veach3, Heather A Zierhut4.   

Abstract

The development of hereditary cancer genetic testing panels has altered genetic counseling practice. Mutations within certain genes on cancer panels pose not only a cancer risk, but also a reproductive risk for autosomal recessive conditions such as Fanconi anemia, constitutional mismatch repair deficiency syndrome, and ataxia telangiectasia. This study aimed to determine if genetic counselors discuss reproductive risks for autosomal recessive conditions associated with genes included on cancer panels, and if so, under what circumstances these risks are discussed. An on-line survey was emailed through the NSGC list-serv. The survey assessed 189 cancer genetic counselors' experiences discussing reproductive risks with patients at risk to carry a mutation or variant of uncertain significance (VUS) in a gene associated with both an autosomal dominant cancer risk and an autosomal recessive syndrome. Over half (n = 82, 55 %) reported having discussed reproductive risks; the remainder (n = 66, 45 %) had not. Genetic counselors who reported discussing reproductive risks primarily did so when patients had a positive result and were of reproductive age. Reasons for not discussing these risks included when a patient had completed childbearing or when a VUS was identified. Most counselors discussed reproductive risk after obtaining results and not during the informed consent process. There is inconsistency as to if and when the discussion of reproductive risks is taking place. The wide variation in responses suggests a need to develop professional guidelines for when and how discussions of reproductive risk for autosomal recessive conditions identified through cancer panels should occur with patients.

Entities:  

Keywords:  Ataxia telangiectasia; Cancer genetic counseling; Cancer panels; Cancer risk; Constitutional mismatch repair deficiency syndrome; Fanconi anemia; Reproductive risk

Mesh:

Year:  2015        PMID: 26454646     DOI: 10.1007/s10897-015-9892-y

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  48 in total

1.  Fanconi anemia gene mutations in young-onset pancreatic cancer.

Authors:  Michiel S van der Heijden; Charles J Yeo; Ralph H Hruban; Scott E Kern
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

2.  Fanconi anemia is associated with a defect in the BRCA2 partner PALB2.

Authors:  Bing Xia; Josephine C Dorsman; Najim Ameziane; Yne de Vries; Martin A Rooimans; Qing Sheng; Gerard Pals; Abdellatif Errami; Eliane Gluckman; Julian Llera; Weidong Wang; David M Livingston; Hans Joenje; Johan P de Winter
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

3.  Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.

Authors:  John E Wagner; Akemi Ishida-Yamamoto; John A McGrath; Maria Hordinsky; Douglas R Keene; David T Woodley; Mei Chen; Megan J Riddle; Mark J Osborn; Troy Lund; Michelle Dolan; Bruce R Blazar; Jakub Tolar
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

4.  Mutations in BRIP1 confer high risk of ovarian cancer.

Authors:  Thorunn Rafnar; Daniel F Gudbjartsson; Patrick Sulem; Aslaug Jonasdottir; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Soren Besenbacher; Pär Lundin; Simon N Stacey; Julius Gudmundsson; Olafur T Magnusson; Louise le Roux; Gudbjorg Orlygsdottir; Hafdis T Helgadottir; Hrefna Johannsdottir; Arnaldur Gylfason; Laufey Tryggvadottir; Jon G Jonasson; Ana de Juan; Eugenia Ortega; Jose M Ramon-Cajal; Maria D García-Prats; Carlos Mayordomo; Angeles Panadero; Fernando Rivera; Katja K H Aben; Anne M van Altena; Leon F A G Massuger; Mervi Aavikko; Paula M Kujala; Synnöve Staff; Lauri A Aaltonen; Kristrun Olafsdottir; Johannes Bjornsson; Augustine Kong; Anna Salvarsdottir; Hafsteinn Saemundsson; Karl Olafsson; Kristrun R Benediktsdottir; Jeffrey Gulcher; Gisli Masson; Lambertus A Kiemeney; Jose I Mayordomo; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

5.  Mutation of the RAD51C gene in a Fanconi anemia-like disorder.

Authors:  Fiona Vaz; Helmut Hanenberg; Beatrice Schuster; Karen Barker; Constanze Wiek; Verena Erven; Kornelia Neveling; Daniela Endt; Ian Kesterton; Flavia Autore; Franca Fraternali; Marcel Freund; Linda Hartmann; David Grimwade; Roland G Roberts; Heiner Schaal; Shehla Mohammed; Nazneen Rahman; Detlev Schindler; Christopher G Mathew
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

6.  XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer.

Authors:  Li Jiao; Manal M Hassan; Melissa L Bondy; Robert A Wolff; Douglas B Evans; James L Abbruzzese; Donghui Li
Journal:  Am J Gastroenterol       Date:  2007-11-06       Impact factor: 10.864

7.  Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumours.

Authors:  Jerzy Nowak; Maria Mosor; Iwona Ziółkowska; Malgorzta Wierzbicka; Monika Pernak-Schwarz; Marta Przyborska; Krzysztof Roznowski; Andrzej Pławski; Ryszard Słomski; Danuta Januszkiewicz
Journal:  Eur J Cancer       Date:  2008-02-15       Impact factor: 9.162

Review 8.  Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?

Authors:  Katharina Wimmer; Julia Etzler
Journal:  Hum Genet       Date:  2008-08-18       Impact factor: 4.132

9.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.

Authors:  Sheila Seal; Deborah Thompson; Anthony Renwick; Anna Elliott; Patrick Kelly; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Munaza Ahmed; Katarina Spanova; Bernard North; Lesley McGuffog; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton; Nazneen Rahman
Journal:  Nat Genet       Date:  2006-10-08       Impact factor: 38.330

10.  Standards and guidelines for CFTR mutation testing.

Authors:  Carolyn Sue Richards; Linda A Bradley; Jean Amos; Bernice Allitto; Wayne W Grody; Anne Maddalena; Matthew J McGinnis; Thomas W Prior; Bradley W Popovich; Michael S Watson; Glenn E Palomaki
Journal:  Genet Med       Date:  2002 Sep-Oct       Impact factor: 8.822

View more
  2 in total

1.  Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts.

Authors:  Wei Zhan; Celeste A Shelton; Phil J Greer; Randall E Brand; David C Whitcomb
Journal:  Pancreas       Date:  2018-09       Impact factor: 3.327

2.  Genetic Counseling Clinic at AIIMS (New Delhi).

Authors:  Dhritiman Maitra; Payal Manek; Neha Gupta; Anurag Srivastava
Journal:  Indian J Surg Oncol       Date:  2020-04-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.